WHAT:
Zaldy Tan, MD, a highly respected memory and geriatric medicine specialist at Cedars-Sinai, is available to comment on both sides of the controversy surrounding the Food and Drug Administration’s (FDA) approval of aducanumab for Alzheimer’s.
Aducanumab, the scientific name for the drug developed by Biogen and marketed under the name of Aduhelm, is a monthly intravenous infusion that is intended to slow cognitive decline in patients in the early stages of the disease.
“Aducanumab has been shown to dissolve clumps of beta-amyloid plaque that builds up in the brain of Alzheimer’s patients,” said Tan. “However, studies have been inconclusive as to whether eliminating the plaque in the brain preserves cognitive and functional abilities.”
WHO:
Zaldy Tan, MD, serves as the medical director of the Jona Goldrich Center for Alzheimer’s and Memory Disorders and director of the…
